- Joined
- Jul 26, 2007
- Messages
- 12,746
- Reaction score
- 2,480
Getting dangerously close to that 1 patient: 1 author ratio and for a paper in Green Journal.... 19:14. 21% Rib fracture in IBC (or really any breast cancer treatment) is considered OK ('toxicity is favorable, modest increase in rib fracture' per the highlights)? Why would anyone use a therapy that has not shown to be oncologically more effective when it is clearly more toxic? And this is with IMPT. The cadillac of proton therapy. In contemporary patients treated within the past 6 years. Way better than passive scattering, which is like the beat up crown-vic of proton therapy. And still. Still has 21% of rib fracture. Is this considered advancing the field? Is the conclusion not "Oh, man, lots of rib fractures, maybe this isn't the best idea"? If not, why not?
But don't you dare use IMRT for breast cancer! Ever!
Financial toxicity! Fractions!